Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 8
Submit an article Journal homepage
202
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editor

Rituximab-induced serum sickness in a patient with follicular lymphoma

P. Disperati Department of Medicine, Queens University, Kingston, ON, Canada
,
L. K. Hicks Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, ON, CanadaCorrespondence[email protected]
&
R. Buckstein Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, ON, Canada
Pages 1633-1635 | Received 09 Feb 2007, Accepted 04 May 2007, Published online: 01 Jul 2009

References

  • D'Arcy C A, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44: 1717–1718
  • Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002; 70: 329
  • Hellerstedt B, Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003; 14: 1792
  • Catuogno M, Rezai S, Priori R, Magrini L, Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford) 2005; 44: 406
  • Wang J, Wiley J M, Luddy R, Greenberg J, Feuerstein M A, Bussel J B. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005; 146: 217–221
  • Pijpe J, van Imhoff G W, Spijkervet F K, Roodenburg J L, Wolbink G J, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52: 2740–2750
  • Bennett C M, Rogers Z R, Kinnamon D D, Bussel J B, Mahoney D H, Abshire T C, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107: 2639–2642
  • Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis 2006
  • Devauchelle-Pensec V, Pennec Y, Morvan J, Pers J O, Daridon C, Jousse-Joulin S, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum 2007; 57: 310–317
  • Finger E, Scheinberg M. Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia. J Clin Rheumatol 2007; 13: 94–95
  • Schutgens R E. Rituximab-induced serum sickness. Br J Haematol 2006; 135: 147
  • Portlock C S, O'Connor O A, Straus D J, Rosenzweig L, Dumitrescu O, Lin O, et al. Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: is there CD20 antigen upregulation?. Leuk Lymphoma 2006; 47: 1260–1264
  • Todd D J, Helfgott S M. Serum sickness following treatment with rituximab. J Rheumatol 2007; 34: 430–433

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.